Health Economics and Outcomes Research

A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.
Researchers have identified follow-up care and outcomes disparities for patients with brain metastasis treated with stereotactic radiosurgery in a private hospital compared with those treated in a safety-net hospital.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
The percentage of US adults under age 65 who skip essential prescription drugs because of price has declined, a five-year study found. But consistently, problems with financial access to medication were more common in cancer survivors.
Chemotherapy drug waste from single-dose vials increased 3-year incremental budget costs by over $100 million in Canada, but is not being modeled uniformly in economic evaluations.
Navigating Cancer’s triage software with the inclusion of symptom management pathways for cancer treatments has saved cancer care providers $3.4 million annually.
The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.
More than 23% of patients with breast cancer who undergo breast-conserving surgery followed by subsequent surgery do not receive the full benefits of surgery due to added costs and complications.
A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.
Four leading national cancer organizations recently issued a joint position statement in order to help guide the future of cancer health disparities research.